Reduced serum brain-derived neurotrophic factor in patients with first onset vitiligo
Yükleniyor...
Dosyalar
Tarih
2014
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Dove Medical Press Ltd
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Purpose: Vitiligo is an acquired pigmentary skin disease that can cause serious cosmetic problems. There have been numerous and well established studies that have demonstrated the comorbidity of various psychiatric disorders in patients with vitiligo. However, to our knowledge, there have been no studies investigating whether a psychiatric biomarker, such as brain-derived neurotrophic factor (BDNF), is associated with vitiligo. Patients and methods: This study was conducted in Namik Kemal University Medical Faculty, Departments of Dermatology and Psychiatry between January 2013 and September 2014. After meeting inclusion and exclusion criteria, serum BDNF levels were assayed in 57 patients with first onset vitiligo and no known current or past psychiatric disorder and compared with BDNF levels in 58 age and sex matched healthy subjects. Results: The age and female/male ratios were similar between groups. The mean values of serum BDNF were 1.57 +/- 0.97 ng/dL and 2.37 +/- 1.73 ng/dL in the vitiligo group and in the healthy control group, respectively. The mean BDNF level was significantly higher in the healthy control group compared with the vitiligo group (t=2.76, P=0.007). Conclusion: This is the first study to compare serum BDNF levels between patients with vitiligo and healthy subjects. The reduced level of serum BDNF in patients with vitiligo may be directly related to the etiology of vitiligo or associated with the high percentage of psychiatric disorders in that patient population. Further studies are needed to support our preliminary results.
Açıklama
Anahtar Kelimeler
neurotrophin, psychosomatic, skin, disease, Nerve Growth-Factor, Life Quality Index, Atopic-Dermatitis Patients, Keratinocyte Apoptosis, Psychiatric Morbidity, Major Depression, Human Epidermis, Mood Disorders, Hair Follicle, Substance-P
Kaynak
Neuropsychiatric Disease and Treatment
WoS Q Değeri
Q3
Scopus Q Değeri
Q2
Cilt
10
